Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 4/2020

21.05.2020 | Research Article

Evaluation of a collaborative care program for pulmonary hypertension patients: a multicenter randomized trial

verfasst von: Matthieu Roustit, Marie-Camille Chaumais, Claire Chapuis, Anne Gairard-Dory, Caroline Hadjadj, Sébastien Chanoine, Benoît Allenet, Olivier Sitbon, Christophe Pison, Pierrick Bedouch, for the ETHAP Study Group

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Background Pulmonary hypertension is a rare, chronic and life-threatening group of diseases. Recent advances in pulmonary hypertension management prolong survival and improve quality-of-life. However, highly complex drug therapy enhances the risk of drug-related problems. Objective To assess the impact of involving clinical pharmacists in the collaborative care of pulmonary hypertension patients. Setting Ten French University Hospital Pneumology departments, all members of the French Network for Pulmonary Hypertension. Methods This prospective multicenter randomized controlled trial included incident pulmonary hypertension patients who were followed-up for 18 months. Randomization using an adapted Zelen method allocated patients to collaborative care (n = 41) or usual care groups (n = 51). A collaborative care program involving clinical pharmacists was developed through a close partnership between with physicians, nurses and pharmacists. Besides usual care, the program includes regular one-to-one interviews between the pharmacist and the patient. These interviews had following objectives: to perform an exhaustive medication history review; to identify the patient’ needs, knowledge and skills; to define educational objectives and to provide patients with relevant information when needed. Following each interview, a standardized report form containing the pharmacist’s recommendations was provided to physicians and nurses and discussed collaboratively. An ancillary economic analysis was performed. Main outcome measure Number of drug-related problems and their outcomes. Results The number of drug-related problems was not significantly different between groups (1.6 ± 1.5 vs. 1.9 ± 2.4; p = 0.41). More problems were resolved in the collaborative care group than in the usual care group (86.5% vs. 66.7%, p = 0.01). Time to clinical worsening, therapeutic adherence, satisfaction or quality-of-life were not statistically different between groups. Collaborative care decreased costs of drug-related hospitalizations. Conclusion Including clinical pharmacists in the multidisciplinary care of hospitalized patients with pulmonary hypertension improved the outcome of drug-related problems and reduced the costs of related hospitalization. However, we observed no efficacy on medication errors, clinical outcomes or medication adherence. Clinical Trial Registration ClinicalTrials.gov Identifier NCT01038284.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Humbert M, Lau EMT, Montani D, Jaïs X, Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014;130:2189–208.CrossRef Humbert M, Lau EMT, Montani D, Jaïs X, Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014;130:2189–208.CrossRef
2.
Zurück zum Zitat Leendertse AJ, Egberts ACG, Stoker LJ, van den Bemt PMLA, HARM Study Group. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med. 2008;168:1890–6.PubMed Leendertse AJ, Egberts ACG, Stoker LJ, van den Bemt PMLA, HARM Study Group. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med. 2008;168:1890–6.PubMed
3.
Zurück zum Zitat Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.CrossRef Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.CrossRef
4.
Zurück zum Zitat Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2015;46:903–75.CrossRef Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2015;46:903–75.CrossRef
6.
Zurück zum Zitat Bedouch P, Roustit M, Quetant S, Chapuis C, Baudrant-Boga M, Lehmann A, et al. Development of a pharmacist collaborative care program for pulmonary arterial hypertension. Int J Clin Pharm. 2011;33:898–901.CrossRef Bedouch P, Roustit M, Quetant S, Chapuis C, Baudrant-Boga M, Lehmann A, et al. Development of a pharmacist collaborative care program for pulmonary arterial hypertension. Int J Clin Pharm. 2011;33:898–901.CrossRef
7.
Zurück zum Zitat Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023–30.CrossRef Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023–30.CrossRef
8.
Zurück zum Zitat Zelen M. A new design for randomized clinical trials. N Engl J Med. 1979;300:1242–5.CrossRef Zelen M. A new design for randomized clinical trials. N Engl J Med. 1979;300:1242–5.CrossRef
9.
Zurück zum Zitat van den Bemt PM, Egberts TC, de Jong-van den Berg LT, Brouwers JR. Drug-related problems in hospitalised patients. Drug Saf. 2000;22:321–33.CrossRef van den Bemt PM, Egberts TC, de Jong-van den Berg LT, Brouwers JR. Drug-related problems in hospitalised patients. Drug Saf. 2000;22:321–33.CrossRef
11.
Zurück zum Zitat McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galie N, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S97–107.CrossRef McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galie N, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S97–107.CrossRef
12.
Zurück zum Zitat Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74.CrossRef Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74.CrossRef
13.
Zurück zum Zitat Lehmann A, Aslani P, Ahmed R, Celio J, Gauchet A, Bedouch P, et al. Assessing medication adherence: options to consider. Int J Clin Pharm. 2014;36:55–69.CrossRef Lehmann A, Aslani P, Ahmed R, Celio J, Gauchet A, Bedouch P, et al. Assessing medication adherence: options to consider. Int J Clin Pharm. 2014;36:55–69.CrossRef
14.
Zurück zum Zitat Ruiz MA, Pardo A, Rejas J, Soto J, Villasante F, Aranguren JL. Development and validation of the “Treatment Satisfaction with Medicines Questionnaire” (SATMED-Q). Value Health. 2008;11:913–26.CrossRef Ruiz MA, Pardo A, Rejas J, Soto J, Villasante F, Aranguren JL. Development and validation of the “Treatment Satisfaction with Medicines Questionnaire” (SATMED-Q). Value Health. 2008;11:913–26.CrossRef
15.
Zurück zum Zitat Delestras S, Roustit M, Bedouch P, Minoves M, Dobremez V, Mazet R, et al. Comparison between two generic questionnaires to assess satisfaction with medication in chronic diseases. PLoS ONE. 2013;8:e56247.CrossRef Delestras S, Roustit M, Bedouch P, Minoves M, Dobremez V, Mazet R, et al. Comparison between two generic questionnaires to assess satisfaction with medication in chronic diseases. PLoS ONE. 2013;8:e56247.CrossRef
16.
Zurück zum Zitat Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Cresswell K, Eden M, et al. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. Lancet Lond Engl. 2012;379:1310–9.CrossRef Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Cresswell K, Eden M, et al. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. Lancet Lond Engl. 2012;379:1310–9.CrossRef
17.
Zurück zum Zitat Rothschild JM, Churchill W, Erickson A, Munz K, Schuur JD, Salzberg CA, et al. Medication errors recovered by emergency department pharmacists. Ann Emerg Med. 2010;55:513–21.CrossRef Rothschild JM, Churchill W, Erickson A, Munz K, Schuur JD, Salzberg CA, et al. Medication errors recovered by emergency department pharmacists. Ann Emerg Med. 2010;55:513–21.CrossRef
18.
Zurück zum Zitat Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006;166:955–64.CrossRef Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006;166:955–64.CrossRef
19.
Zurück zum Zitat Kripalani S, Roumie CL, Dalal AK, Cawthon C, Businger A, Eden SK, et al. Effect of a pharmacist intervention on clinically important medication errors after hospital discharge: a randomized trial. Ann Intern Med. 2012;157:1–10.CrossRef Kripalani S, Roumie CL, Dalal AK, Cawthon C, Businger A, Eden SK, et al. Effect of a pharmacist intervention on clinically important medication errors after hospital discharge: a randomized trial. Ann Intern Med. 2012;157:1–10.CrossRef
20.
Zurück zum Zitat Murray MD, Ritchey ME, Wu J, Tu W. Effect of a pharmacist on adverse drug events and medication errors in outpatients with cardiovascular disease. Arch Intern Med. 2009;169:757–63.CrossRef Murray MD, Ritchey ME, Wu J, Tu W. Effect of a pharmacist on adverse drug events and medication errors in outpatients with cardiovascular disease. Arch Intern Med. 2009;169:757–63.CrossRef
21.
Zurück zum Zitat Griffin F, Resar R. IHI global trigger tool for measuring adverse events. 2nd ed. Cambridge: Institute for Healthcare Improvement; 2009. Griffin F, Resar R. IHI global trigger tool for measuring adverse events. 2nd ed. Cambridge: Institute for Healthcare Improvement; 2009.
22.
Zurück zum Zitat O’Leary KJ, Devisetty VK, Patel AR, Malkenson D, Sama P, Thompson WK, et al. Comparison of traditional trigger tool to data warehouse based screening for identifying hospital adverse events. BMJ Qual Saf. 2013;22:130–8.CrossRef O’Leary KJ, Devisetty VK, Patel AR, Malkenson D, Sama P, Thompson WK, et al. Comparison of traditional trigger tool to data warehouse based screening for identifying hospital adverse events. BMJ Qual Saf. 2013;22:130–8.CrossRef
23.
Zurück zum Zitat Bedouch P, Charpiat B, Conort O, Rose FX, Escofier L, Juste M, et al. Assessment of clinical pharmacists’ interventions in French hospitals: results of a multicenter study. Ann Pharmacother. 2008;42:1095–103.CrossRef Bedouch P, Charpiat B, Conort O, Rose FX, Escofier L, Juste M, et al. Assessment of clinical pharmacists’ interventions in French hospitals: results of a multicenter study. Ann Pharmacother. 2008;42:1095–103.CrossRef
24.
Zurück zum Zitat Carter B. Cluster size variability and imbalance in cluster randomized controlled trials. Stat Med. 2010;29:2984–93.CrossRef Carter B. Cluster size variability and imbalance in cluster randomized controlled trials. Stat Med. 2010;29:2984–93.CrossRef
25.
Zurück zum Zitat Guittet L, Ravaud P, Giraudeau B. Planning a cluster randomized trial with unequal cluster sizes: practical issues involving continuous outcomes. BMC Med Res Methodol. 2006;6:17.CrossRef Guittet L, Ravaud P, Giraudeau B. Planning a cluster randomized trial with unequal cluster sizes: practical issues involving continuous outcomes. BMC Med Res Methodol. 2006;6:17.CrossRef
26.
Zurück zum Zitat Campbell R, Peters T, Grant C, Quilty B, Dieppe P. Adapting the randomized consent (Zelen) design for trials of behavioural interventions for chronic disease: feasibility study. J Health Serv Res Policy. 2005;10:220–5.CrossRef Campbell R, Peters T, Grant C, Quilty B, Dieppe P. Adapting the randomized consent (Zelen) design for trials of behavioural interventions for chronic disease: feasibility study. J Health Serv Res Policy. 2005;10:220–5.CrossRef
27.
Zurück zum Zitat Ellenberg SS. Randomization designs in comparative clinical trials. N Engl J Med. 1984;310:1404–8.CrossRef Ellenberg SS. Randomization designs in comparative clinical trials. N Engl J Med. 1984;310:1404–8.CrossRef
28.
Zurück zum Zitat Hugon A, Roustit M, Lehmann A, Saint-Raymond C, Borrel E, Hilleret M-N, et al. Influence of intention to adhere, beliefs and satisfaction about medicines on adherence in solid organ transplant recipients. Transplantation. 2014;98:222–8.CrossRef Hugon A, Roustit M, Lehmann A, Saint-Raymond C, Borrel E, Hilleret M-N, et al. Influence of intention to adhere, beliefs and satisfaction about medicines on adherence in solid organ transplant recipients. Transplantation. 2014;98:222–8.CrossRef
29.
Zurück zum Zitat Waxman A, Chen S-Y, Boulanger L, Watson JA, Golden G. Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension. J Med Econ. 2013;16:298–306.CrossRef Waxman A, Chen S-Y, Boulanger L, Watson JA, Golden G. Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension. J Med Econ. 2013;16:298–306.CrossRef
Metadaten
Titel
Evaluation of a collaborative care program for pulmonary hypertension patients: a multicenter randomized trial
verfasst von
Matthieu Roustit
Marie-Camille Chaumais
Claire Chapuis
Anne Gairard-Dory
Caroline Hadjadj
Sébastien Chanoine
Benoît Allenet
Olivier Sitbon
Christophe Pison
Pierrick Bedouch
for the ETHAP Study Group
Publikationsdatum
21.05.2020
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 4/2020
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-020-01047-8

Weitere Artikel der Ausgabe 4/2020

International Journal of Clinical Pharmacy 4/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.